Featured Article: Differential regulation of endothelial nitric oxide synthase phosphorylation by protease-activated receptors in adult human endothelial cells

• Published in: Experimental biology and medicine (Maywood, N.J.) Vol. 241; no. 6; pp. 569 - 580
• Main Authors: Tillery, Lakeisha C, Epperson, Tenille A, Eguchi, Satoru, Motley, Evangeline D
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.03.2016
• Subjects: Adult; Cells, Cultured; Endothelial Cells - enzymology; Endothelial Cells - physiology; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Nitric Oxide - metabolism; Nitric Oxide Synthase Type III - metabolism; Original Research; Phosphorylation; Protein Processing, Post-Translational; Receptor, PAR-1 - metabolism; Receptor, PAR-2 - metabolism; Receptors, Thrombin - metabolism; Young Adult; protease-activated receptors; nitric oxide; thrombin; Endothelial nitric-oxide synthase; endothelial dysfunction
• ISSN: 1535-3702; 1535-3699
• DOI: 10.1177/1535370215622584

Protease-activated receptors have been shown to regulate endothelial nitric oxide synthase through the phosphorylation of specific sites on the enzyme. It has been established that PAR-2 activation phosphorylates eNOS-Ser-1177 and leads to the production of the potent vasodilator nitric oxide, while PAR-1 activation phosphorylates eNOS-Thr-495 and decreases nitric oxide production in human umbilical vein endothelial cells. In this study, we hypothesize a differential coupling of protease-activated receptors to the signaling pathways that regulates endothelial nitric oxide synthase and nitric oxide production in primary adult human coronary artery endothelial cells. Using Western Blot analysis, we showed that thrombin and the PAR-1 activating peptide, TFLLR, lead to the phosphorylation of eNOS-Ser-1177 in human coronary artery endothelial cells, which was blocked by SCH-79797 (SCH), a PAR-1 inhibitor. Using the nitrate/nitrite assay, we also demonstrated that the thrombin- and TFLLR-induced production of nitric oxide was inhibited by SCH and L-NAME, a NOS inhibitor. In addition, we observed that TFLLR, unlike thrombin, significantly phosphorylated eNOS-Thr-495, which may explain the observed delay in nitric oxide production in comparison to that of thrombin. Activation of PAR-2 by SLIGRL, a PAR-2 specific ligand, leads to dual phosphorylation of both catalytic sites but primarily regulated eNOS-Thr-495 phosphorylation with no change in nitric oxide production in human coronary artery endothelial cells. PAR-3, known as the non-signaling receptor, was activated by TFRGAP, a PAR-3 mimicking peptide, and significantly induced the phosphorylation of eNOS-Thr-495 with minimal phosphorylation of eNOS-Ser-1177 with no change in nitric oxide production. In addition, we confirmed that PAR-mediated eNOS-Ser-1177 phosphorylation was Ca2+-dependent using the Ca2+ chelator, BAPTA, while eNOS-Thr-495 phosphorylation was mediated via Rho kinase using the ROCK inhibitor, Y-27632, suggesting protease-activated receptor coupling to Gq and G12/13, respectively. These data suggest a vascular bed specific differential coupling of protease-activated receptors to the signaling pathways that regulate endothelial nitric oxide synthase and nitric oxide production that may be responsible for endothelial dysfunction associated with cardiovascular disease.